A phase IIb trial of Heartcel in patients with moderate to severe adult heart failure
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2018
Price : $35 *
At a glance
- Drugs Immunomodulatory-progenitor-cell-therapy-Celixir (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Celixir
- 08 Jun 2018 According to a Celixir media release, the US FDA has approved an IND application for Heartcel. This approval allows the expansion of this study to the US clinical trial sites.
- 11 Jan 2018 New trial record
- 08 Jan 2018 According to a Celixir media release, this trial is expected to complete in 2020.